Esmo 2019 preview – immunotherapies grab the rest of the late-breaker focus

Full readout of data from two recently toplined studies looks set to be the highlight for immunotherapies at this month’s Esmo meeting. Keytruda’s Keynote-522 trial in triple-negative breast cancer and Tecentriq’s Imvigor-130 test in bladder cancer were both said to be positive, and both have secured late-breaker slots.